PMV Pharmaceuticals公布Rezatapopt单药疗法治疗卵巢癌的最新积极中期数据

美股速递
Sep 01

PMV Pharmaceuticals今日宣布,其Rezatapopt单药疗法在Pynnacle二期关键试验中,针对卵巢癌患者的最新中期数据展现出令人鼓舞的疗效。

这些数据进一步巩固了该药物作为潜在治疗方案的临床价值,为后续研发路径提供了有力支撑。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10